Dr Teng Leyan, PhD, Joins Aether AI as a Strategic Advisor
February 14th, 2025, We are excited to announce the addition of Teng Leyan, PhD, as a strategic advisor. Dr. Teng is the founder of R&G (Stock Code: 301333 SZ), a leading clinical research organization with a global footprint. Her background includes a Doctorate in Clinical Pharmacology from the NUS and an EMBA from Tsinghua University. She has also spent more than a decade at Lilly Clinical Pharmacology Center, refining clinical trial methodologies to improve patient outcomes and streamline pharmaceutical innovation.
Under her leadership, R&G has grown into a powerhouse of nearly 2,000 professionals, providing comprehensive CRO services that support pharmaceutical enterprises in enhancing drug development success rates, mitigating risks, reducing costs, and accelerating clinical research timelines.
Dr. Teng’s extensive business acumen and leadership experience will be instrumental in shaping Aether AI’s broader strategic initiatives. Her ability to navigate complex regulatory landscapes, manage large-scale operations, and drive innovation will help Aether AI expand its influence across multiple industries. Her insights will provide valuable guidance as we continue to invest in, develop and scale AI-driven solutions that address business challenges.
About Aether AI
Aether AI operates as a hybrid between a venture studio and a VC, investing in, acquiring, and developing niche artificial intelligence startups. Our in-house research and development team collaborates with visionary founders and industry leaders to build transformative AI solutions across healthcare, finance, and emerging technology sectors. With a mission to bridge innovation and real-world applications, Aether AI is committed to pioneering AI advancements that enhance industries and improve lives.
